Tema ETFs LLC Trims Stock Position in BridgeBio Pharma, Inc. $BBIO

Tema ETFs LLC lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 32.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 76,076 shares of the company’s stock after selling 36,197 shares during the quarter. Tema ETFs LLC’s holdings in BridgeBio Pharma were worth $5,666,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. First Bank & Trust grew its holdings in BridgeBio Pharma by 1.6% during the second quarter. First Bank & Trust now owns 8,797 shares of the company’s stock worth $655,000 after acquiring an additional 142 shares during the period. GAMMA Investing LLC raised its position in BridgeBio Pharma by 13.8% during the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock valued at $123,000 after acquiring an additional 199 shares in the last quarter. Harbor Investment Advisory LLC acquired a new position in BridgeBio Pharma in the second quarter valued at approximately $137,000. Parallel Advisors LLC lifted its holdings in BridgeBio Pharma by 552.6% in the first quarter. Parallel Advisors LLC now owns 894 shares of the company’s stock valued at $66,000 after acquiring an additional 757 shares during the period. Finally, Avidity Partners Management LP purchased a new stake in BridgeBio Pharma in the 1st quarter worth approximately $711,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BBIO shares. Citigroup raised their price objective on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. HC Wainwright increased their price target on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Raymond James Financial lowered shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $110.00 price objective on shares of BridgeBio Pharma in a report on Tuesday. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.53.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Hannah Valantine sold 2,196 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total transaction of $150,579.72. Following the transaction, the director directly owned 9,259 shares of the company’s stock, valued at $634,889.63. This trade represents a 19.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of BridgeBio Pharma stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the completion of the sale, the director owned 22,579 shares in the company, valued at approximately $1,896,636. This trade represents a 43.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 392,117 shares of company stock worth $29,934,700 in the last ninety days. Company insiders own 14.23% of the company’s stock.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong commercial growth: Second-quarter revenue rose 120.4% year over year to $243.68 million, exceeding the $220.91 million consensus estimate. Attruby U.S. net sales reportedly increased 311% year over year, while ex-U.S. Beyonttra royalties rose 62% sequentially. BridgeBio reaffirmed guidance for more than $1 billion in combined 2026 Attruby and Beyonttra global sales and expects three product launches by mid-2027. BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
• Positive Sentiment: Analyst optimism increased: Piper Sandler raised its price target to $115, TD Cowen to $110, Bank of America to $104 and Wells Fargo to $102; all maintained positive ratings. Morgan Stanley trimmed its target slightly to $97 but retained an Overweight rating. These targets imply substantial upside from recent trading levels. Analyst price target updates
• Positive Sentiment: Pipeline catalysts remain in focus: BridgeBio is among biotechnology companies expected to have potentially important second-half 2026 clinical or regulatory catalysts, which may support investor interest in the shares. Four Biotech Stocks With Major Second-Half Pipeline Catalysts
• Neutral Sentiment: Limited short-interest signal: Reported short interest was zero shares as of August 11, unchanged from the prior period, so short covering is unlikely to be a meaningful driver of the current move.
• Neutral Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees under Nasdaq’s inducement-grant exception. The grants support hiring but could result in modest future dilution. BridgeBio Pharma Reports Inducement Grants
• Negative Sentiment: Quarterly loss missed expectations: BBIO reported a loss of $0.78 per share, wider than the $0.58 consensus estimate, although the loss improved from $0.95 per share a year earlier. The earnings shortfall likely outweighed the revenue beat in near-term trading. BridgeBio Pharma Q2 Earnings Results

BridgeBio Pharma Trading Down 1.1%

Shares of BBIO opened at $83.70 on Wednesday. BridgeBio Pharma, Inc. has a 12 month low of $46.81 and a 12 month high of $93.42. The stock’s 50 day moving average is $76.47 and its two-hundred day moving average is $73.07. The firm has a market cap of $16.36 billion, a P/E ratio of -23.45 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. BridgeBio Pharma’s quarterly revenue was up 120.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.95) EPS. Equities research analysts forecast that BridgeBio Pharma, Inc. will post -2.31 EPS for the current year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.